

PRIMARY SERIES: 2-dose series of an mRNA COVID 19 vaccine; at this time, only the Pfizer-BioNTech primary series is FDA-approved or FDA-authorized for children and adolescents aged 5-17 years. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children aged < 5 years.

ADDITIONAL PRIMARY DOSE: subsequent dose of vaccine that should be administered ONLY to moderately to severely immunocompromised people ≥ 12 years who received a 2-dose mRNA COVID-19 vaccine primary series; the additional primary dose should be the same vaccine manufacturer as the primary series.

- Moderately to severely immunocompromised people include those who have:
 - Been receiving active cancer treatment for tumors or cancers of the blood
 - Received an organ transplant and are taking medicine to suppress the immune system
 - Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
 - Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
 - Advanced or untreated HIV infection
 - Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

BOOSTER DOSE: subsequent dose of vaccine that can be administered to teens aged 16-17 years after primary series or after additional primary dose in moderately to severely immunocompromised people; the booster dose should be the same vaccine manufacturer as the primary series/additional primary dose.


REFERENCES

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently approved or Authorized in the United States. Cdc.gov.

Updated November 19, 2021.

www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#overview-covid19-vax-recommendations.

UPDATED DECEMBER 14, 2021.



PRIMARY SERIES: 2-dose series of an mRNA COVID-19 vaccine (Pfizer-BioNTech and Moderna) or a single dose of Janssen vaccine; if choosing a 2-dose series, the same vaccine manufacturer should be used for both doses.

ADDITIONAL PRIMARY DOSE: subsequent dose of vaccine that should be administered **ONLY** to moderately to severely immunocompromised people ≥ 12 years who received a 2-dose mRNA COVID-19 vaccine primary series; the additional primary dose should be the same vaccine manufacturer as the primary series.

- Moderately to severely immunocompromised people include those who have:
- Been receiving active cancer treatment for tumors or cancers of the blood
 - Received an organ transplant and are taking medicine to suppress the immune system
 - Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
 - Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
 - Advanced or untreated HIV infection
 - Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

BOOSTER DOSE: subsequent dose of vaccine that should be administered to people ≥ 18 years after primary series or after additional primary dose in moderately to severely immunocompromised people; the booster dose can be a different vaccine manufacturer than the primary series/additional primary dose.

REFERENCES:
 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently approved or Authorized in the United States. Cdc.gov. Updated November 19, 2021.
www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#overview-covid19-vax-recommendations.